PARP inhibitors present a novel, innovative and personalized treatment option for MGMT unmethylated GBM patients; however, clinical trials are currently ongoing and analyses need to be completed before adding PARP inhibitors to the standard treatment of GBM. This evidence concerns the gene MGMT and glioblastoma.